Modelling hepatitis C therapy—predicting effects of treatment
Abstract
Mathematically modelling changes in HCV RNA levels measured in patients who receive antiviral therapy has yielded many insights into the pathogenesis and effects of treatment on the virus. By determining how rapidly HCV is cleared when viral replication is interrupted by a therapy, one can deduce how rapidly the virus is produced in patients before treatment. This knowledge, coupled with estimates of the HCV mutation rate, enables one to estimate the frequency with which drug resistant variants arise. Modelling HCV also permits the deduction of the effectiveness of an antiviral agent at blocking HCV replication from the magnitude of the initial viral decline. One can also estimate the lifespan of an HCV-infected cell from the slope of the subsequent viral decline and determine the duration of therapy needed to cure infection. The original understanding of HCV RNA decline under interferon-based therapies obtained by modelling needed to be revised in order to interpret the HCV RNA decline kinetics seen when using direct-acting antiviral agents (DAAs). In addition, there also exist unresolved issues involving understanding therapies with combinations of DAAs, such as the presence of detectable HCV RNA at the end of therapy in patients who nonetheless have a sustained virologic response.
- Authors:
-
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- INSERM, IAME, UMR, Univ. Paris Diderot, Paris (France)
- Publication Date:
- Research Org.:
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 1236682
- Report Number(s):
- LA-UR-15-20073
Journal ID: ISSN 1759-5045
- Grant/Contract Number:
- AC52-06NA25396
- Resource Type:
- Journal Article: Accepted Manuscript
- Journal Name:
- Nature Reviews. Gastroenterology & Hepatology
- Additional Journal Information:
- Journal Volume: 12; Journal Issue: 8; Journal ID: ISSN 1759-5045
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES; Biological Science
Citation Formats
Perelson, Alan S., and Guedj, Jeremie. Modelling hepatitis C therapy—predicting effects of treatment. United States: N. p., 2015.
Web. doi:10.1038/nrgastro.2015.97.
Perelson, Alan S., & Guedj, Jeremie. Modelling hepatitis C therapy—predicting effects of treatment. United States. https://doi.org/10.1038/nrgastro.2015.97
Perelson, Alan S., and Guedj, Jeremie. Tue .
"Modelling hepatitis C therapy—predicting effects of treatment". United States. https://doi.org/10.1038/nrgastro.2015.97. https://www.osti.gov/servlets/purl/1236682.
@article{osti_1236682,
title = {Modelling hepatitis C therapy—predicting effects of treatment},
author = {Perelson, Alan S. and Guedj, Jeremie},
abstractNote = {Mathematically modelling changes in HCV RNA levels measured in patients who receive antiviral therapy has yielded many insights into the pathogenesis and effects of treatment on the virus. By determining how rapidly HCV is cleared when viral replication is interrupted by a therapy, one can deduce how rapidly the virus is produced in patients before treatment. This knowledge, coupled with estimates of the HCV mutation rate, enables one to estimate the frequency with which drug resistant variants arise. Modelling HCV also permits the deduction of the effectiveness of an antiviral agent at blocking HCV replication from the magnitude of the initial viral decline. One can also estimate the lifespan of an HCV-infected cell from the slope of the subsequent viral decline and determine the duration of therapy needed to cure infection. The original understanding of HCV RNA decline under interferon-based therapies obtained by modelling needed to be revised in order to interpret the HCV RNA decline kinetics seen when using direct-acting antiviral agents (DAAs). In addition, there also exist unresolved issues involving understanding therapies with combinations of DAAs, such as the presence of detectable HCV RNA at the end of therapy in patients who nonetheless have a sustained virologic response.},
doi = {10.1038/nrgastro.2015.97},
url = {https://www.osti.gov/biblio/1236682},
journal = {Nature Reviews. Gastroenterology & Hepatology},
issn = {1759-5045},
number = 8,
volume = 12,
place = {United States},
year = {2015},
month = {6}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Search WorldCat to find libraries that may hold this journal
Cited by: 14 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection
journal, March 2014
- Gane, Edward J.; Stedman, Catherine A.; Hyland, Robert H.
- Gastroenterology, Vol. 146, Issue 3
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
journal, January 1995
- Ho, David D.; Neumann, Avidan U.; Perelson, Alan S.
- Nature, Vol. 373, Issue 6510
Decay characteristics of HIV-1-infected compartments during combination therapy
journal, May 1997
- Perelson, Alan S.; Essunger, Paulina; Cao, Yunzhen
- Nature, Vol. 387, Issue 6629
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
journal, March 1996
- Perelson, A. S.; Neumann, A. U.; Markowitz, M.
- Science, Vol. 271, Issue 5255
Viral dynamics in human immunodeficiency virus type 1 infection
journal, January 1995
- Wei, Xiping; Ghosh, Sajal K.; Taylor, Maria E.
- Nature, Vol. 373, Issue 6510
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
journal, October 1998
- Neumann, A. U.
- Science, Vol. 282, Issue 5386
Modeling Subgenomic Hepatitis C Virus RNA Kinetics during Treatment with Alpha Interferon
journal, April 2009
- Dahari, H.; Sainz, B.; Perelson, A. S.
- Journal of Virology, Vol. 83, Issue 13
Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents
journal, September 2013
- Rong, Libin; Perelson, Alan S.
- Mathematical Biosciences, Vol. 245, Issue 1
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
journal, June 2003
- Herrmann, E.
- Hepatology, Vol. 37, Issue 6
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004
- Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
- Nature, Vol. 432, Issue 7019
Antiviral action of ribavirin in chronic hepatitis C
journal, March 2004
- Pawlotsky, Jean-Michel; Dahari, Harel; Neumann, Avidan U.
- Gastroenterology, Vol. 126, Issue 3
Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders
journal, May 2006
- Talal, Andrew H.; Ribeiro, Ruy M.; Powers, Kimberly A.
- Hepatology, Vol. 43, Issue 5
Triphasic decline of hepatitis C virus RNA during antiviral therapy
journal, January 2007
- Dahari, Harel; Ribeiro, Ruy M.; Perelson, Alan S.
- Hepatology, Vol. 46, Issue 1
Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy
journal, July 2007
- Dahari, Harel; Lo, Arthur; Ribeiro, Ruy M.
- Journal of Theoretical Biology, Vol. 247, Issue 2
Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis
journal, January 2009
- Reluga, Timothy C.; Dahari, Harel; Perelson, Alan S.
- SIAM Journal on Applied Mathematics, Vol. 69, Issue 4
Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
journal, September 2010
- Dahari, Harel; Affonso de Araujo, Evaldo S.; Haagmans, Bart L.
- Journal of Hepatology, Vol. 53, Issue 3
Hepatocyte Proliferation and Hepatitis C Virus Kinetics During Treatment
journal, January 2011
- Dahari, H.; Rong, L.; Layden, T. J.
- Clinical Pharmacology & Therapeutics, Vol. 89, Issue 3
Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors
journal, April 2012
- Reddy, Micaela B.; Morcos, Peter N.; Le Pogam, Sophie
- Antimicrobial Agents and Chemotherapy, Vol. 56, Issue 6
A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response
journal, August 2014
- Nguyen, T. H. T.; Mentré, F.; Levi, M.
- Clinical Pharmacology & Therapeutics, Vol. 96, Issue 5
HCV Kinetic Models and Their Implications in Drug Development: HCV Kinetic Models and Their Implications
journal, April 2015
- Nguyen, Tht; Guedj, J.
- CPT: Pharmacometrics & Systems Pharmacology, Vol. 4, Issue 4
The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus
journal, February 2006
- Dixit, N. M.; Perelson, A. S.
- Cellular and Molecular Life Sciences, Vol. 63, Issue 7-8
Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals?
journal, May 2012
- Feld, Jordan J.
- Gastroenterology, Vol. 142, Issue 6
Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling
journal, July 2010
- Feld, Jordan J.; Lutchman, Glen A.; Heller, Theo
- Gastroenterology, Vol. 139, Issue 1
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
journal, February 2013
- Rotman, Yaron; Noureddin, Mazen; Feld, Jordan J.
- Gut, Vol. 63, Issue 1
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models
journal, October 2010
- Thomas, Emmanuel; Feld, Jordan J.; Li, Qisheng
- Hepatology, Vol. 53, Issue 1
Review article: predicting response in hepatitis C virus therapy
journal, April 2006
- Mihm, U.; Herrmann, E.; Sarrazin, C.
- Alimentary Pharmacology and Therapeutics, Vol. 23, Issue 8
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV
journal, January 2014
- Canini, Laetitia; Chatterjee, Anushree; Guedj, Jeremie
- Antiviral Therapy, Vol. 20, Issue 5
A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis
journal, August 2014
- Conway, Jessica M.; Perelson, Alan S.
- PLoS Computational Biology, Vol. 10, Issue 8
Modeling HCV kinetics under therapy using PK and PD information
journal, March 2009
- Shudo, Emi; Ribeiro, Ruy M.; Perelson, Alan S.
- Expert Opinion on Drug Metabolism & Toxicology, Vol. 5, Issue 3
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
journal, May 2011
- Guedj, Jeremie; Perelson, Alan S.
- Hepatology, Vol. 53, Issue 6
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)
journal, February 2012
- Guedj, Jeremie; Dahari, Harel; Shudo, Emi
- Hepatology, Vol. 55, Issue 4
Analysis of the hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938
journal, January 2014
- Guedj, Jeremie; Pang, Phillip S.; Denning, Jill
- Antiviral Therapy, Vol. 19, Issue 2
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
journal, January 2014
- Canini, Laetitia; DebRoy, Swati; Mariño, Zoe
- Antiviral Therapy, Vol. 20, Issue 2
Viral kinetic modeling: state of the art
journal, June 2014
- Canini, Laetitia; Perelson, Alan S.
- Journal of Pharmacokinetics and Pharmacodynamics, Vol. 41, Issue 5
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
journal, April 2010
- Gao, Min; Nettles, Richard E.; Belema, Makonen
- Nature, Vol. 465, Issue 7294
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013
- Guedj, J.; Dahari, H.; Rong, L.
- Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus
journal, July 2000
- Neumann, Avidan U.; Lam, Nancy P.; Dahari, Harel
- The Journal of Infectious Diseases, Vol. 182, Issue 1
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model
journal, March 2013
- Rong, Libin; Guedj, Jeremie; Dahari, Harel
- PLoS Computational Biology, Vol. 9, Issue 3
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
journal, August 2014
- McGivern, David R.; Masaki, Takahiro; Williford, Sara
- Gastroenterology, Vol. 147, Issue 2
Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle
journal, March 2015
- McGivern, David R.; Masaki, Takahiro; Lovell, William
- Journal of Virology, Vol. 89, Issue 10
Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
journal, September 2014
- Meredith, Luke W.; Farquhar, Michelle J.; Tarr, Alexander W.
- Hepatology, Vol. 60, Issue 6
Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells
journal, October 2006
- Dahari, H.; Ribeiro, R. M.; Rice, C. M.
- Journal of Virology, Vol. 81, Issue 2
Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle
journal, August 2013
- Binder, Marco; Sulaimanov, Nurgazy; Clausznitzer, Diana
- PLoS Pathogens, Vol. 9, Issue 8
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010
- Snoeck, E.; Chanu, P.; Lavielle, M.
- Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
journal, March 2010
- Reesink, Henk W.; Fanning, Gregory C.; Farha, Khalid Abou
- Gastroenterology, Vol. 138, Issue 3
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
journal, December 2002
- Blight, K. J.; McKeating, J. A.; Rice, C. M.
- Journal of Virology, Vol. 76, Issue 24
Novel Hepatitis C Virus Reporter Replicon Cell Lines Enable Efficient Antiviral Screening against Genotype 1a
journal, June 2010
- Robinson, M.; Yang, H.; Sun, S. -C.
- Antimicrobial Agents and Chemotherapy, Vol. 54, Issue 8
A double whammy for hep C
journal, June 2003
- Farley, Suzanne
- Nature Reviews Drug Discovery, Vol. 2, Issue 6
Antiviral Suppression vs Restoration of RIG-I Signaling by Hepatitis C Protease and Polymerase Inhibitors
journal, November 2008
- Liang, Yuqiong; Ishida, Hisashi; Lenz, Oliver
- Gastroenterology, Vol. 135, Issue 5
Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial
journal, August 2013
- Osinusi, Anuoluwapo; Meissner, Eric G.; Lee, Yu-Jin
- JAMA, Vol. 310, Issue 8
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics
journal, December 2010
- Guedj, J.; Neumann, A. U.
- Journal of Theoretical Biology, Vol. 267, Issue 3
Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients
journal, June 2014
- Laouénan, Cédric; Marcellin, Patrick; Lapalus, Martine
- Antimicrobial Agents and Chemotherapy, Vol. 58, Issue 9
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice
journal, March 2015
- Cento, Valeria; Tontodonati, Monica; Di Maio, Velia Chiara
- Digestive and Liver Disease, Vol. 47, Issue 3
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
journal, March 2015
- Kohli, Anita; Osinusi, Anuoluwapo; Sims, Zayani
- The Lancet, Vol. 385, Issue 9973
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy
journal, March 2015
- Sarrazin, Christoph; Wedemeyer, Heiner; Cloherty, Gavin
- Journal of Virological Methods, Vol. 214
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
journal, October 2010
- Gane, Edward J.; Roberts, Stuart K.; Stedman, Catherine AM
- The Lancet, Vol. 376, Issue 9751
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study
journal, June 2014
- Gane, Edward J.; Pockros, Paul J.; Zeuzem, Stefan
- Liver International, Vol. 35, Issue 1
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
journal, May 2014
- Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender
- New England Journal of Medicine, Vol. 370, Issue 20
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
journal, March 2015
- Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan
- The Lancet, Vol. 385, Issue 9973
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells
journal, March 2008
- Colombatto, P.; Ciccorossi, P.; Maina, Am
- Clinical Pharmacology & Therapeutics, Vol. 84, Issue 2
A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection
journal, January 2012
- Adiwijaya, Bambang S.; Kieffer, Tara L.; Henshaw, Joshua
- PLoS Computational Biology, Vol. 8, Issue 1
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients: HEPATOLOGY, Vol. XX, NO. X, 2014 GUEDJ ET AL.
journal, April 2014
- Guedj, Jeremie; Yu, Jing; Levi, Micha
- Hepatology, Vol. 59, Issue 5
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
journal, September 2007
- Kieffer, Tara L.; Sarrazin, Christoph; Miller, Janice S.
- Hepatology, Vol. 46, Issue 3
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
journal, April 2010
- Adiwijaya, Bambang S.; Herrmann, Eva; Hare, Brian
- PLoS Computational Biology, Vol. 6, Issue 4
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
journal, August 2012
- Ribeiro, Ruy M.; Li, Hui; Wang, Shuyi
- PLoS Pathogens, Vol. 8, Issue 8
Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo
journal, March 2009
- Cuevas, J. M.; Gonzalez-Candelas, F.; Moya, A.
- Journal of Virology, Vol. 83, Issue 11
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
journal, May 2010
- Rong, L.; Dahari, H.; Ribeiro, R. M.
- Science Translational Medicine, Vol. 2, Issue 30
Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
journal, August 2014
- Haseltine, Eric L.; De Meyer, Sandra; Dierynck, Inge
- PLoS Computational Biology, Vol. 10, Issue 8
Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor
journal, May 2012
- Rong, Libin; Ribeiro, Ruy M.; Perelson, Alan S.
- Bulletin of Mathematical Biology, Vol. 74, Issue 8
Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes
journal, February 2007
- Schaller, T.; Appel, N.; Koutsoudakis, G.
- Journal of Virology, Vol. 81, Issue 9
Superinfection Exclusion in Cells Infected with Hepatitis C Virus
journal, February 2007
- Tscherne, D. M.; Evans, M. J.; von Hahn, T.
- Journal of Virology, Vol. 81, Issue 8
Evasion of Superinfection Exclusion and Elimination of Primary Viral RNA by an Adapted Strain of Hepatitis C Virus
journal, October 2013
- Webster, B.; Ott, M.; Greene, W. C.
- Journal of Virology, Vol. 87, Issue 24
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin
journal, December 2014
- Hedskog, Charlotte; Doehle, Brian; Chodavarapu, Krishna
- Hepatology, Vol. 61, Issue 2
Modeling Within-Host Dynamics of Influenza Virus Infection Including Immune Responses
journal, June 2012
- Pawelek, Kasia A.; Huynh, Giao T.; Quinlivan, Michelle
- PLoS Computational Biology, Vol. 8, Issue 6
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy
journal, May 2007
- Lee, J. J.; Kong, M.; Ayers, G. D.
- Journal of Biopharmaceutical Statistics, Vol. 17, Issue 3
1172 Antiviral Activity and Resistance Profile of the Novel hcv ns5a Inhibitor Gs-5885
journal, April 2012
- Cheng, G.; Peng, B.; Corsa, A.
- Journal of Hepatology, Vol. 56
Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
journal, March 2015
- Sidharthan, Sreetha; Kohli, Anita; Sims, Zayani
- Clinical Infectious Diseases, Vol. 60, Issue 12
Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
journal, March 2013
- Sáez-Cirión, Asier; Bacchus, Charline; Hocqueloux, Laurent
- PLoS Pathogens, Vol. 9, Issue 3
Post-treatment control of HIV infection
journal, April 2015
- Conway, Jessica M.; Perelson, Alan S.
- Proceedings of the National Academy of Sciences, Vol. 112, Issue 17
Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro.
journal, July 1993
- Shimizu, Y. K.; Purcell, R. H.; Yoshikura, H.
- Proceedings of the National Academy of Sciences, Vol. 90, Issue 13
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
journal, July 2013
- Lawitz, Eric; Poordad, Fred; Kowdley, Kris V.
- Journal of Hepatology, Vol. 59, Issue 1
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C
journal, January 2013
- Soriano, Vincent; Vispo, Eugenia; de Mendoza, Carmen
- Antiviral Therapy, Vol. 18, Issue 8
Very late HCV relapse following triple therapy for hepatitis C
journal, January 2014
- Barreiro, Pablo; Vispo, Eugenia; Maida, Ivana
- Antiviral Therapy, Vol. 19, Issue 7
Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses
journal, February 2011
- Veerapu, Naga Suresh; Raghuraman, Sukanya; Liang, T. Jake
- Gastroenterology, Vol. 140, Issue 2
Interferon γ–Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response
journal, June 2014
- Lin, Jennifer C.; Habersetzer, François; Rodriguez-Torres, Maribel
- The Journal of Infectious Diseases, Vol. 210, Issue 12
Works referencing / citing this record:
Mathematical modeling of within-host Zika virus dynamics
journal, August 2018
- Best, Katharine; Perelson, Alan S.
- Immunological Reviews, Vol. 285, Issue 1
Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016
journal, June 2018
- Chirikov, Viktor V.; Marx, Steven E.; Manthena, Shivaji R.
- Advances in Therapy, Vol. 35, Issue 7
Mathematical modeling of within-host Zika virus dynamics
journal, August 2018
- Best, Katharine; Perelson, Alan S.
- Immunological Reviews, Vol. 285, Issue 1
Mathematical Models for Immunology: Current State of the Art and Future Research Directions
journal, October 2016
- Eftimie, Raluca; Gillard, Joseph J.; Cantrell, Doreen A.
- Bulletin of Mathematical Biology, Vol. 78, Issue 10
Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies
journal, August 2017
- Best, Katharine; Guedj, Jeremie; Madelain, Vincent
- Proceedings of the National Academy of Sciences, Vol. 114, Issue 33
Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
journal, August 2018
- Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
- Immunological Reviews, Vol. 285, Issue 1